000			02216nam a2200469 i 4500
999			_c277760 _d277760
001			on1078151833
003			OCoLC
005			20190115102942.0
007			he bmb024bbca
008			181206s2018 dcua bb f000 0 eng c
040			_aPUCPR _beng _erda _cGPO _dMvI
042			_apcc
043			_an-us---
074			_a1019-B-01 (MF)
086	0		_aY 4.C 73/8:115-88
088			_aSerial no. 115-88 (United States. Congress. House. Committee on Energy and Commerce)
099			_aY 4.C 73/8:115-88
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce. _bSubcommittee on Health,
245	1	0	_aExamining the drug supply chain : _bhearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, December 13, 2017.
264		1	_aWashington : _bU.S. Government Publishing Office, _c2018.
300			_avi, 320 pages : _billustrations ; _c24 cm
336			_btxt
337			_bh _2rdamedia
338			_bhe _2rdacarrier
500			_aShipping list no.: 2018-0213-M.
500			_a"Serial No. 115-88."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
533			_aMicrofiche. _b[Washington, D.C.] : _cU.S. Government Printing Office, _d[2018] _e4 microfiches : negative.
776	0	8	_iOnline version: _aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. _tExamining the drug supply chain _w(OCoLC)1043948909
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. _tExamining the drug supply chain _w(DLC) 2018379840 _w(OCoLC)1043948698
050		4	_aKF27 _b.E553 2017c
650		0	_aDrugs _xPrescribing _zUnited States.
650		0	_aPrescription pricing _zUnited States.
650		0	_aMedicine _xResearch _zUnited States.
650		0	_aGeneric drugs _xDevelopment _zUnited States.
650		0	_aCompetition _zUnited States.
650		0	_aConsumer protection _zUnited States.
650		0	_aHealth services accessibility _zUnited States.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8